-
2022-502046-28-00
5
2023-12-22
HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
-
2022-502332-39-00
4
2023-11-15
Tuberous sclerosis complex (TSC)
-
2023-503661-28-00
5
2023-10-26
Hidradenitis Suppurativa
-
2023-503558-10-00
5
2023-10-13
oligometastatic pancreatic cancer
-
2022-501515-14-00
5
2023-09-29
Newly Diagnosed Multiple Myeloma (NDMM)
-
2022-502732-39-00
10
2023-09-01
Previously treated non-ocular advanced melanoma
-
2022-503133-54-00
7
2023-08-09
Solid Tumors
-
2024-512320-11-00
5
2023-08-09
Primary diffuse large B-cell lymphoma of the central nervous system
(P
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2024-517885-40-00
6
2023-07-03
Chronic Kidney Disease (CKD)
-
2024-514022-23-00
4
2023-06-23
Early breast cancer
-
2022-500699-76-00
5
2023-05-18
Active Systemic Lupus Erythematosus (SLE)
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2024-516819-24-00
9
2023-05-16
Systemic Sclerosis
-
2022-501238-52-00
10
2023-03-23
Heart failure due to systemic left ventricular systolic dysfunction
-
2023-505634-94-00
10
2023-02-02
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2023-508129-28-00
9
2022-09-28
Pediatric patients with Philadelphia chromosome positive chronic myelo
-
2023-508868-30-00
5
2022-09-26
Treatment of stereotypical prolonged seizure
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2024-510950-29-00
5
2022-07-21
Stereotypical prolonged seizure
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma